ArticleFrontiers in oncology2022

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation.

Chaoyuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.